Imipramine is used in the treatment of depression, such as depression associated with agitation or anxiety and has similar efficacy to the antidepressant drug moclobemide.  It has also been used to treat nocturnal enuresis because of its ability to decrease the delta-wave stage of sleep where this occurs.
Imipramine was, in the late 1950s, the first tricyclic antidepressant to be developed (by Ciba). At the first international congress of neuro-pharmacology in Rome, September 1958 Dr Freyhan from the University of Pennsylvania, USA, discussed as one of the first clinicians the effects of imipramine in a group of 46 patients, most of them were diagnosed as 'depressive psychosis'. The patients were selected for this study based on symptoms such as depressive apathy, kinetic retardation and feelings of hopelessness and despair. In 30% of all patients he reported 'optimal results and in around 20% failure. The side effects noted were classified as ' atropine-like and most patients suffered from dizziness. Imipramine was first tried against psychotic disorders, such as schizophrenia, but proved insufficient. As an antidepressant, it did well in clinical studies and it is known to work well in even the most severe cases of depression. It is not surprising, therefore, that Imipramine is also known to cause a high rate of manic and hypomanic reactions, especially in patients with preexisting bipolar disorder. It is estimated that up to 25% of such patients maintained on Imipramine will switch into mania or hypomania. Such powerful antidepressant properties have made it favorable in the treatment of treatment-resistant depression.
At the advent of SSRIs, its sometimes intolerable side-effect profile became more tolerable. Therefore, it became extensively used as a standard antidepressant and later served as a prototypical drug for the development of the later-released tricyclics. It is not as commonly used today, but is sometimes used to treat major depression as a second-line treatment. It has also seen limited use in the treatment of migraines, ADHD, and post concussive syndrome. Imipramine has additional indications for the treatment of panic attacks, chronic pain, and Kleine-Levin syndrome. In pediatric patients, it is relatively frequently used to treat pavor nocturnus and nocturnal enuresis.
Imipramine, tertiary amine, affects numerous neurotransmitter systems known to be involved in the etiology of depression, anxiety, ADHD, enuresis and numerous other mental and physical conditions. Imipramine is similar in structure to some muscle relaxants, and has a significant analgesic effect and, thus, is very useful in some pain conditions.
The mechanisms of Imipramine's medicinal action include, but are not limited to, effects on:
Serotonin (5-HT): Very strong reuptake inhibition. Imipramine has the second highest attraction for the serotonin transporter (SERT) in the tricyclic antidepressant class behind clomipramine. This provides a very strong and proportional effect on the blockade of serotonin reuptake. Moderating this effect, however, is imipramine's continual conversion in the body to its metabolite desipramine, which has extremely strong and relatively selective noradrenergic effects. This blend of imipramine and desipramine circulating together within the body provides a powerful one-two punch in simultaneously blockading both serotonin and norepinephrine reuptake.
Dopamine (DA): Reuptake and release at D1 and D2 receptors. Similar but less potent than psychostimulants, dopamine agonists, and the atypical antidepressant bupropion on dopaminergic mechanisms (increase in release and blockade of reuptake inhibition). While this effect is much less than the primary effects on NE, SER and ACh, it is nonetheless significant and is partially responsible for the therapeutic benefits of treatment with Imipramine. Enhancement of brain dopamine activity has been implicated in Imipramine's ability to stimulate motor activity and prolong time spent in escape in mice. Regarding dopamine uptake, imipramine is far less potent than most other antidepressants (for example, it has only 5% of the potency of amitriptyline or paroxetine, see the table below).
Acetylcholine (ACh): Imipramine is an anticholinergic. Thus, it is prescribed with caution to the elderly and with extreme caution to those with psychosis, as the general brain activity enhancement in combination with the "dementing" effects of anticholinergics increases the potential of Imipramine to cause hallucinations, confusion and delirium in this population. Imipramine is an antagonist at M2 muscarinic acetylcholine receptors (see external links). The blockade of cholinergic (muscarine) receptors is known to cause euphoria, potentially contributing to the mood lifting effects of Imipramine as well. Antimuscarinic effect is also responsible for rapid heart rate (tachycardia).
Epinephrine: Imipramine antagonizes adreno-receptors (II), thus sometimes causing increased heart rate (contributed to by other effects as well), orthostatic hypotension, and a general decrease in the responsiveness of the central nervous system (hence, a contribution to its potent anti-anxiety properties).
σ receptor and Enkephalinase: Activity on σ-receptors is present, but it is very low (Ki of 520 nM on σ-receptors, see references) and it is about half the power of amitryptiline (300 nM).
Histamine: Imipramine is an antagonist at histamine H1 receptors. This contributes to the acute sedative effect that it has in most people. In turn, its anti-histaminergic and general calming effects take place immediately, and, thus, Imipramine is sometimes prescribed as a sleep aid in low doses.
BDNF: BDNF is implicated in neurogenesis in the hippocampus, and studies suggest that depressed patients have decreased levels of BDNF and reduced hippocampal neurogenesis. It is not clear how neurogenesis restores mood, as ablation of hippocampal neurogenesis in murine models do not show anxiety related or depression related behaviours. Chronic Imipramine administration results in increased histone acetylation (which is associated with transcriptional activation and decondensed chromatin) at the hippocampal BDNF promotor, and also reduced expression of hippocampal HDAC5.
μ receptor: Imipramine has been shown to increase the expression of μ-opioid receptors in rat forebrain.
The symptoms and the treatment of an imipramine overdose are largely the same as for the other tricyclic antidepressants. Cardinal symptoms are cardiac (tachycardia, widened QRS complex) and neurological disturbances. Any ingestion by children should be considered as serious and potentially fatal.
^Heck, HA; Buttrill, JE Jr; Flynn, NW; Dyer, RL; Anbar, M; Cairns, T; Dighe, S; Cabana, BE (June 1979). "Bioavailability of imipramine tablets relative to a stable isotope-labelled internal standard: increasing the power of bioavailability tests". Journal of Pharmacokinetics and Biopharmaceutics7 (3): 233-248. PMID480146.
^Delini-Stula A, Mikkelsen H, Angst J (October 1995). "Therapeutic efficacy of antidepressants in agitated anxious depression--a meta-analysis of moclobemide studies". J Affect Disord35 (1–2): 21–30. doi:10.1016/0165-0327(95)00034-K. PMID8557884.
^Healy, David: The Antidepressant Era, page 211. Harvard University Press, 1997.
^Bottlender R, Rudolf D, Strauss A, Möller HJ (1998). "Antidepressant-associated maniform states in acute treatment of patients with bipolar-I depression". European Archives of Psychiatry and Clinical Neuroscience248 (6): 296–300. doi:10.1007/s004060050053. PMID9928908.
^Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ (April 2006). "Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action". Nature Neuroscience9 (4): 519–25. doi:10.1038/nn1659. PMID16501568.
^de Gandarias, JM; Echevarria, E; Acebes, I; Silio, M; Casis, L (1998 Jul). "Effects of imipramine administration on mu-opioid receptor immunostaining in the rat forebrain.". Arzneimittel-Forschung48 (7): 717–9. PMID9706370.Check date values in: |date= (help)
^National Institute of Mental Health. PDSD Ki Database (Internet) [cited 2013 Jul 28]. Chapel Hill (NC): University of North Carolina. 1998-2013. Available from: http://pdsp.med.unc.edu/pdsp.php
^Brunton L, Chabner B, Knollman B. Goodman and Gilman’s The Pharmacological Basis of Therapeutics, Twelfth Edition. McGraw Hill Professional; 2010.
^Skidmore-Roth, L.(ed.). (2010). Mosby's Nursing Drug Reference (23rd ed.). St. Louis, MO: Mosby Elsevier.